J Clin Neurol.  2014 Oct;10(4):354-357. 10.3988/jcn.2014.10.4.354.

Fulminant Subacute Sclerosing Panencephalitis Presenting with Acute Ataxia and Hemiparesis in a 15-Year-Old Boy

Affiliations
  • 1Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, India. rukminimridula@gmail.com
  • 2Department of Pathology, Nizam's Institute of Medical Sciences, Hyderabad, India.
  • 3Department of Neurology, Medical College Hospital, Trivandrum, Kerala, India.

Abstract

BACKGROUND
Subacute sclerosing panencephalitis (SSPE) is a delayed and fatal manifestation of measles infection. Fulminant SSPE is a rare presentation in which the disease progresses to death over a period of 6 months. The clinical features are atypical and can be misleading.
CASE REPORT
We report herein a teenage boy who presented with acute-onset gait ataxia followed by right hemiparesis that evolved over 1 month, with left-hemispheric, delta-range slowing on the electroencephalogram (EEG). Magnetic resonance imaging disclosed multiple white-matter hyperintensities, suggesting a diagnosis of acute disseminated encephalomyelitis. He received intravenous steroids, and within 4 days of hospital admission he developed unilateral slow myoclonic jerks. Repeat EEG revealed Rademecker complexes, pathognomonic of SSPE, and an elevated titer of IgG antimeasles antibodies was detected in his cerebrospinal fluid. The disease progressed rapidly and the patient succumbed within 15 days of hospitalization. The diagnosis of SSPE was confirmed by autopsy.
CONCLUSIONS
This case illustrates the difficulty of recognizing fulminant SSPE when it manifests with asymmetric clinical and EEG abnormalities.

Keyword

measles; asymmetric presentation; steroids; autopsy; GFAP

MeSH Terms

Adolescent*
Antibodies
Ataxia*
Autopsy
Cerebrospinal Fluid
Diagnosis
Electroencephalography
Encephalomyelitis, Acute Disseminated
Gait Ataxia
Hospitalization
Humans
Immunoglobulin G
Magnetic Resonance Imaging
Male
Measles
Myoclonus
Paresis*
Steroids
Subacute Sclerosing Panencephalitis*
Antibodies
Immunoglobulin G
Steroids

Figure

  • Fig. 1 A: Initial EEG of the patient disclosed quasirhythmic, high-amplitude, 3- to 4-Hz delta activity with an amplitude of 150 µV over the entire left hemisphere, with normal background activity of 9-10 Hz over the right hemisphere. B: EEG on day 4 of hospitalization disclosed generalized long-interval, high-amplitude, periodic complexes (250-300 µV) lasting about 1 second, with a slow background of low-amplitude activity (40 µV), with an interburst interval of about 7-8 seconds.

  • Fig. 2 Fluid-attenuated inversion recovery images of brain magnetic resonance imaging scans showing bilateral posterior-predominant subcortical and periventricular hyperintensities.

  • Fig. 3 Pathological features noted in brain on autopsy. A: Coronal section of the patient's brain with areas of gray discoloration and softening in the parietal cortex and corpus callosum (scale bar=1 cm). B: Axial section of the midbrain showing areas of grayish discoloration (scale bar=1 cm). C: Hematoxylin-and-eosin-stained section showing the presence of Cowdry A inclusions within neurons and oligodendrocytes (inset; scale bar=5 µm). D: Measles antigen within neurons (immunostaining with a human IgG antimeasles antibody; scale bar=5 µm).


Reference

1. Gutierrez J, Issacson RS, Koppel BS. Subacute sclerosing panencephalitis: an update. Dev Med Child Neurol. 2010; 52:901–907.
Article
2. Mahadevan A, Vaidya SR, Wairagkar NS, Khedekar D, Kovoor JM, Santosh V, et al. Case of fulminant-SSPE associated with measles genotype D7 from India: an autopsy study. Neuropathology. 2008; 28:621–626.
Article
3. Sarkar N, Gulati S, Dar L, Broor S, Kalra V. Diagnostic dilemmas in fulminant subacute sclerosing panencephalitis (SSPE). Indian J Pediatr. 2004; 71:365–367.
Article
4. Ekici B, Calişkan M, Tatli B, Aydinli N, Ozmen M. Rapidly progressive subacute sclerosing panencephalitis presenting with acute loss of vision. Acta Neurol Belg. 2011; 111:325–327.
5. Hergüner MO, Altunbaşak S, Baytok V. Patients with acute, fulminant form of SSPE. Turk J Pediatr. 2007; 49:422–425.
6. Katrak SM, Mahadevan A, Taly AB, Sinha S, Shankar SK. A 16-year old male with cortical blindness and focal motor seizures. Ann Indian Acad Neurol. 2010; 13:225–232.
Article
7. Tuncel D, Ozbek AE, Demirpolat G, Karabiber H. Subacute sclerosing panencephalitis with generalized seizure as a first symptom: a case report. Jpn J Infect Dis. 2006; 59:317–319.
8. Kravljanac R, Jovic N, Djuric M, Nikolic L. Epilepsia partialis continua in children with fulminant subacute sclerosing panencephalitis. Neurol Sci. 2011; 32:1007–1012.
Article
9. Komur M, Arslankoylu AE, Okuyaz C, Kuyucu N. Atypical clinical course subacute sclerosing panencephalitis presenting as acute Encephalitis. J Pediatr Neurosci. 2012; 7:120–122.
Article
10. Cherian A, Sreedharan S, Raghavendra S, Nayak D, Radhakrishnan A. Periodic lateralized epileptiform discharges in fulminant form of SSPE. Can J Neurol Sci. 2009; 36:524–526.
Article
11. Ozyürek H, Değerliyurt A, Turanli G. Subacute sclerosing panencephalitis presenting with hemiparesis in childhood: case report. J Child Neurol. 2003; 18:363–365.
Article
12. Dyken PR. Subacute sclerosing panencephalitis. Current status. Neurol Clin. 1985; 3:179–196.
13. Yaramiş A, Taşkesen M. Brainstem involvement in subacute sclerosing panencephalitis. Turk J Pediatr. 2010; 52:542–545.
14. Sharma P, Singh D, Singh MK, Garg RK, Kohli N. Brainstem involvement in subacute sclerosing panencephalitis. Neurol India. 2011; 59:273–275.
Article
15. Prashanth LK, Taly AB, Ravi V, Sinha S, Rao S. Long term survival in subacute sclerosing panencephalitis: an enigma. Brain Dev. 2006; 28:447–452.
Article
16. Serdaroglu G, Kutlu A, Tekgul H, Tutuncuoglu S. Subacute sclerosing panencephalitis: a case with fulminant course after ACTH. Pediatr Neurol. 2004; 31:67–70.
Article
Full Text Links
  • JCN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr